Does Rallies show 13F holders for BCRX?

Yes. Rallies tracks hedge fund and 13F ownership data for BCRX, including fund names, share counts, latest tracked quarter, and position changes when available.

Is BCRX research on Rallies investment advice?

No. Rallies provides research, data, and educational context for BCRX. It does not provide personalized investment advice.

BCRX (BioCryst Pharmaceuticals Inc) Stock Analysis - Hedge Fund Holdings

BioCryst Pharmaceuticals Inc (BCRX) is a publicly traded Healthcare sector company. As of May 21, 2026, BCRX trades at $8.72 with a market cap of $2.28B and a P/E ratio of -5.07. BCRX moved -0.34% today. Year to date, BCRX is +17.95%; over the trailing twelve months it is -15.39%. Its 52-week range spans $6.00 to $11.31. Analyst consensus is strong buy with an average price target of $22.43. Rallies surfaces BCRX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns BCRX stock?

Hedge funds tracked by Rallies that own BCRX include Orbimed Advisors, Bridgewater Associates, Panagora Asset, and Farallon Capital. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for BioCryst Pharmaceuticals Inc.

BCRX Key Metrics

Key financial metrics for BCRX
Metric	Value
Price	$8.72
Market Cap	$2.28B
P/E Ratio	-5.07
EPS	$-1.73
Dividend Yield	0.00%
52-Week High	$11.31
52-Week Low	$6.00
Volume	1.02K
Avg Volume	0
Revenue (TTM)	$885.72M
Net Income	$-457.98M
Gross Margin	97.75%

Top Hedge Funds Holding BCRX

Orbimed Advisors holds 1.43M shares of BCRX, changed -18.18% as of Mar 31, 2026.
Bridgewater Associates holds 638.05K shares of BCRX, changed +170.85% as of Mar 31, 2026.
Panagora Asset holds 88.88K shares of BCRX, changed +0.00% as of Mar 31, 2026.
Farallon Capital holds 24.00K shares of BCRX, changed +0.00% as of Mar 31, 2026.

Latest BCRX News

BioCryst Reports $721.8M Q1 Loss, $156.4M Revenue and Strong ORLADEYO Sales — May 6, 2026
BioCryst Q1 ORLADEYO Revenue Up 11%; Europe Navenibart License Brings $70M — May 6, 2026
BioCryst Taps Sandeep Menon to Drive navenibart BLA, Astria Integration — Apr 6, 2026
BioCryst’s Price Target Raised to $22 as Q4 EPS Hits $1.12 on $406.5M Revenue — Mar 10, 2026
BioCryst Posts $601M ORLADEYO Revenue, $214M Profit and Pellets Launch — Mar 6, 2026

Recent BCRX Insider Trades

Barnes Alane P sold 62.50K (~$596.25K) on May 13, 2026.
HEGGIE THERESA sold 49.93K (~$504.82K) on Mar 20, 2026.
Barnes Alane P sold 150.00K (~$1.37M) on Mar 16, 2026.

BCRX Analyst Consensus

8 analysts cover BCRX: 0 strong buy, 8 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $22.43.

Common questions about BCRX

Who owns BCRX stock?: Hedge funds tracked by Rallies that own BCRX include Orbimed Advisors, Bridgewater Associates, Panagora Asset, and Farallon Capital. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for BioCryst Pharmaceuticals Inc.
Does Rallies show 13F holders for BCRX?: Yes. Rallies tracks hedge fund and 13F ownership data for BCRX, including fund names, share counts, latest tracked quarter, and position changes when available.
Is BCRX research on Rallies investment advice?: No. Rallies provides research, data, and educational context for BCRX. It does not provide personalized investment advice.